Blue­bird's one-shot gene ther­a­py for be­ta tha­lassemia of­fi­cial­ly se­cures EMA back­ing — ap­proval ex­pect­ed in the sec­ond quar­ter

Days af­ter two char­i­ties abrupt­ly pre­an­nounced that the EMA had en­dorsed the ap­proval of blue­bird bio’s keen­ly an­tic­i­pat­ed gene-re­place­ment ther­a­py Lenti­Glo­bin, for be­ta tha­lassemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.